CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 020181

MICROBIOLOGY REVIEW(S)

REVIEW FOR HFD-510

OFFICE OF NEW DRUG CHEMISTRY MICROBIOLOGY STAFF HFD-805 Microbiologist's Review # 2 of NDA 20-181 July 8, 1996

A. 1. APPLICATION NUMBER:

NDA 20-181

APPEARS THIS MAY ON ORIGINAL

APPLICANT:

Abbott Laboratories Hospital Products Division Abbott Park, IL 60064-3500

2. PRODUCT NAME:

Liposyn III 30% Pharmacy Bulk Package

3. DOSAGE FORM: Sterile fat emulsion in 500 ml and 1000 ml Pharmacy bulk package.

4. METHOD OF STERILIZATION:

5. PHARMACOLOGICAL CATAGORY and/or PRINCIPLE INDICATION: Source of calories in parenteral nutrition.

6. DRUG PRIORITY CLASSIFICATION:

3C

APPEARS THIS WAY ON ORIGINAL

B. 1. DATE OF INITIAL SUBMISSION:

April 10, 1991

2. DATE OF AMENDMENT: May 28, 1996

5. ASSIGNED FOR REVIEW:

June 11, 1996

C. REMARKS:

Microbiologist's Review #1 (dated Oct. 31, 1991) yielded five questions that were subsequently faxed to the applicant on Dec. 3, 1991. The applicant's response(s) to these questions/issues are provided below, and follow the microbiologist's questions provided in italics.

APPEARS THIS WAY

/\$/

D. CONCLUSIONS:

The application is recommended for approval for issues concerning sterility assurance. We acknowledge that Abbott Laboratories has withdrawn the 1000 ml Liposyn III 30 % product size from NDA 20-181.

APPEARS THIS WAY

Neal Sweeney, Ph.D.

7/5/96

CC:

Original NDA 20-181 HFD-510/ Division File HFD-510/CSO/C. Kish HFD-805/Consult File/N. Sweeney

Drafted by: Neal Sweeney, July 8, 1996 R/D initialed by P. Cooney July 8, 1996

APPEARS THIS WAY ON ORIGINAL

APPEARS THIS WAY ON ORIGINAL

Division of Medical Imaging, Surgical and Dental Drug Products Microbiologist's Review No. 1 October 31, 1991

A. 1. Application Number: NDA 20-181

Applicant: Abbott Laboratories

Hospital Products Division Abbott Park, IL 60064-3500

2. Product Name: Liposyn III 30%, Pharmacy Bulk Package

3. Dosage Form: Sterile Fat Emulsion in 500 ml and 1000 ml Pharmacy Bulk Package

4. Method of Sterilization:

5. Pharmacological Category and/or Principle Indication: Source of calories in parenteral nutrition.

6. Drug Priority Classification: 3C

B. 1. Initial Submission: April 10, 1991

2. Amendments: N/A

C. Remarks:

The subject drug product is to be supplied in 500 ml and 1000 ml : containers and will be manufactured at the North Chicago facility as follows:

Container Size	Mfq. Site	Sterilization Process
1000 ml	N. Chicago	
500 ml	N. Chicago	

The manufacturing procedures relative to sterilization

D. Conclusions:

the application is not recommended for approval on the basis of sterility assurance.

/S/

Peter H. Cooney, PhD
Supervisory Microbiologist /S/11/21/41

APPEARS THIS WAY ON ORIGINAL

cc: NDA 20-181

HFD-160/Cooney/Koch/Wilson/Kenealy/McCord

APPEARS THIS WAY
ON ORIGINAL